Mupirocin ointments
In vitro x In vivo bioequivalence evaluation
DOI:
https://doi.org/10.1590/s2175-97902022e19426Keywords:
Mupirocin; Topical bioequivalence; Tape-stripping; Skin; Stratum corneum sampling in vivoAbstract
Bioequivalence (BE) assessment of topical drug products is a long-standing challenge. Agencies such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have published several drafts in recent years suggesting different approaches as alternative to evaluate the BE. A proposed Topical Classification System (TCS) has even been discussed. Given the above, the objective of this research was to use in vitro and in vivo BE approaches to evaluate Brazilian marketed mupirocin (MPC) ointments, previously classified as TCS class The in vitro permeation test (IVPT) was performed by applying formulations to pig skin by Franz cells. The in vivo methodology was dermatopharmacokinetic (DPK). These approaches (in vivo tape stripping and IVPT) demonstrated capability of distinguishing among different formulations, thus making them useful methodologies for BE evaluation.
Downloads
References
Agência Nacional de Vigilância Sanitária, ANVISA. Resolução RDC nº 37, 03 de agosto de 2011. Dispõe sobre o Guia para isenção e substituição de estudos de biodisponibilidade relativa/bioequivalência e dá outras providências. Diário Oficial da União. Brasília, DF.
Agência Nacional de Vigilância Sanitária, ANVISA. Resolução RDC nº 27, de 17 de maio de 2012. Dispõe sobre os requisitos mínimos para a validação de métodos bioanalíticos empregados em estudos com fins de registro e pós-registro de medicamentos. Diário Oficial da União . Brasília, DF.
Araújo TP, Fittipaldi IM, Bedor DCG, Duarte ML, Cordery SF, Guy RH, et al. Topical bio(in)equivalence of metronidazole formulations in vivo. Int J Pharm. 2018;541(1-2):167-172. doi: 10.1016/j.ijpharm.2018.02.032.
» https://doi.org/10.1016/j.ijpharm.2018.02.032.
Braddy AC, Davit BM, Stier EM, Conner DP. Survey of international regulatory bioequivalence recommendations for approval of generic topical dermatological drug products. AAPS J. 2015;17(1):121-133. DOI: 10.1208/s12248-014-9679-3.
» https://doi.org/10.1208/s12248-014-9679-3.
British Pharmacopeia. Mupirocin Ointment. London: Stationery Office, 2008.
Cavalcanti IMFSD, Chagas SCC, Sousa GD, Barbosa ICF, Santana DP, Leal LB. Topical Bioequivalence: Evaluation of Hydrocortisone acetate, Betamethasone valerate and Mupirocin marketed Brazilian products. Lat Am J Pharm. 2019;38(6):1122-9.
Chang RK, Raw A, Lionberger R, Yu L. Generic development of topicaldermatologic products: formulation development, process development, andtesting of topical dermatologic products. AAPS J. 2013;15:41-52.
Conner DP. Differences in DPK Methods. Transcribed presentation to the Advisory Committee for Pharmaceutical Sciences Meeting, Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA), Rockville, MD, November 29, 2001; presentation slides available at http://www.fda.gov/ohrms/dockets/ac/01/slides/3804s2_05_conner/index.htm; transcript of presentation available at http://www.fda.gov/ohrms/dockets/ac/01/transcripts/3804t2_01_Morning_Session.pdf, pp 71-75.
» http://www.fda.gov/ohrms/dockets/ac/01/slides/3804s2_05_conner/index.htm
» http://www.fda.gov/ohrms/dockets/ac/01/transcripts/3804t2_01_Morning_Session.pdf
Cordery SF, Pensado A, Chiu WS, Shehab MZ, Bunge AL, Delgado-Charro MB, et al. Topical bioavailability of diclofenac from locally-acting, dermatological formulations. Int J Pharm . 2017;529(1-2):55-64. doi: 10.1016/j.ijpharm.2017.06.063.
» https://doi.org/10.1016/j.ijpharm.2017.06.063.
De Freitas ZMF, Ricci-junior E, Bemvindo CS, Dos Santos EP, Storpirtis S, Chiann C, et al. Development and characterization of ketoconazole cream to treat superficial mycoses: in vitro permeation and in vivo retention studies. Lat Am J Pharm . 2015;34(7):1304-10.
Ehtier A, Knauer K, Romanski F, Richardson N. The Effect of Emollient Selection on the Microstructure and Release of Clotrimazole from Topical Cream Formulations. file:///D:/Downloads/AAPS%202016%20Emollient%20Selection%20 Poster%20(2).pdf> Accessed in 27 may 2018.
European Medicine Agency (EMA). Draft guideline on quality and equivalence of topical products. 2019.
Franz TJ. Study Avita Gel 0.025% vs Retin-A Gel 0.025%, Transcribed presentation, Advisory Committee for Pharmaceutical Sciences Meeting, Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA), Rockville, MD, November 29, 2001; presentation slides available at http://www.fda.gov/ohrms/dockets/ac/01/slides/3804s2_03_franz.pdf transcript of presentation available at http://www.fda.gov/ohrms/dockets/ac/01/transcripts/3804t2_01_Morning_Session.pdf pp. 47- 61.
» http://www.fda.gov/ohrms/dockets/ac/01/slides/3804s2_03_franz.pdf
» http://www.fda.gov/ohrms/dockets/ac/01/transcripts/3804t2_01_Morning_Session.pdf
French AC, Thompson AL, Davis BG. High Purity Discrete PEG Oligomer Crystals Allow Structural Insight. Angew Chem Int Ed Engl. 2009;48(7):1248-52. doi: 10.1002/anie.200804623.
» https://doi.org/10.1002/anie.200804623.
Herkenne C, Alberti I, Naik A, Kalia YN, Mathy FX, Préat V, et al. In Vivo Methods for the Assessment of Topical Drug Bioavailability. Pharm Res. 2008;25:1. DOI: 10.1007/s11095-007-9429-7.
» https://doi.org/10.1007/s11095-007-9429-7.
Jain P. Bioequivalence of Topical Dosage Forms. J Farmacovigilância 2. 2014;2(2):doi: 10.4172/2329-6887.1000e118.
» https://doi.org/10.4172/2329-6887.1000e118.
Kanfer I. Strategies for the Bioequivalence Assessment of Topical Dermatological Dosage Forms. J Bioequiv Availab. 2010;2(5):102-110. doi: 10.4172/jbb.1000040.
» https://doi.org/10.4172/jbb.1000040.
Krishnaiah YS, Xu X, Rahman Z, Yang Y, Katragadda U, Lionberger R, et al. Development of performance matrix for generic product equivalence of acyclovir topical creams. Int J Pharm . 2014;475,110-122. DOI: 10.1016/j.ijpharm.2014.07.034.
» https://doi.org/10.1016/j.ijpharm.2014.07.034.
Kryscio DR, Sathe PM, Lionberger L, YU L, Bell MA, JAY M, et al. Spreadability Measurements to Assess Structural Equivalence (Q3) of Topical Formulations-A Technical Note. AAPS PharmSciTech. 2008;9(1): DOI: 10.1208/s12249-007-9009-5
» https://doi.org/10.1208/s12249-007-9009-5
Leal LB, Cordery SF, Delgado-Charro MB, Bunge AL, Guy RH. Bioequivalence methodologies for topical drug products: in vitro and ex vivo studies with a corticosteroid and an anti- fungal drug. Pharm Res . 2017;34(4):730-737. doi: 10.1007/s11095-017-2099-1.
» https://doi.org/10.1007/s11095-017-2099-1.
Mitra A, Kim N, Spark D, Toner F, Craig S, Roper C, et al. Use of an in vitro human skin permeation assay to assess bioequivalence of two topical cream formulations containing butenafine hydrochloride (1%, w/w). Regul Toxicol Pharmacol. 82 14 e 19. 2016.
N’Dri-Stempfer B, Navidi WC, Guy RH, Bunge AL. Improved Bioequivalence Assessment of Topical Dermatological Drug Products Using Dermatopharmacokinetics. Pharm Res . 2009;26:2. DOI: 10.1007/s11095-008-9742-9.
» https://doi.org/10.1007/s11095-008-9742-9
Nallagundla S, Patnala S, Kanfer I. Application of an Optimized Tape Stripping Method for the Bioequivalence Assessment of Topical Acyclovir Creams. AAPS PharmSciTech . 2018;19(4):1567-1573. doi: 10.1208/s12249-018-0971-x.
» https://doi.org/10.1208/s12249-018-0971-x
N’Dri-Stempfer B, Navidi WC, Guy RH, Bunge AL. Optimizing metrics for the assessment of bioequivalence between topical drug products. Pharm Res . 2008;25(7):1621- 30. doi: 10.1007/s11095-008-9577-4.
» https://doi.org/10.1007/s11095-008-9577-4
Office of Generic Drugs (OGD), FDA. Draft guidance on ivermectin topical cream, Recommended October 2017a. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM573031.pdf Accessed in 13 november 2017.
» https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM573031.pdf
Office of Generic Drugs (OGD), FDA. Draft guidance on acyclovir, Recommended March 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm296733.pdf Accessed in 13 november 2017.
» http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm296733.pdf
Office of Generic Drugs (OGD), FDA. Draft guidance on acyclovir , Recommended December 2014; Revised December 2016a. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM428195.pdf Accessed in 13 november 2017.
» https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM428195.pdf
Office of Generic Drugs (OGD), FDA. Draft guidance on cyclosporine ophthalmic emulsion, Recommended June 2013; Revised February 2016 and Octuber 2016b. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm358114.pdf Accessed in 13 november 2017.
» https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm358114.pdf
Office of Generic Drugs (OGD), FDA. Draft guidance on docosanol cream, Recommended October 2017b. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM572999.pdf Accessed in 13 november 2017.
» https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM572999.pdf
Office of Generic Drugs (OGD), FDA. Draft guidance on mupirocin topical ointment, Recommended june 2010. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM217138.pdf Accessed in 27 march 2018.
» https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM217138.pdf
Office of Generic Drugs (OGD), FDA. Guidance for industry on special protocol assessment; availability. 2002.
Office of Generic Drugs (OGD), FDA. Guidance for Industry, Nonsterile semisolid dosage forms, scaleup and post-approval changes: chemistry, manufacturing, and control; in vitro release testing and in vivo bioequivalence documentation. 1997.
Office of Generic Drugs (OGD), FDA. Guidance for industry: Topical dermatological drug product NDAS and ANDAS- in vivo bioavailability, bioequivalence, in vitro release, and associated studies. 1998.
Parfitt NR, Skinner MF, Bon C , Kanfer I. Bioequivalence of Topical Clotrimazole formulations: An Improved Tape Stripping Method. J Pharm Pharm Sci. 2011;14(3):347-57.
Pershing LK. Bioequivalence assessment of three 0.025% tretinoin gel products: Dermatopharmacokinetic vs. Clinical Trial Methods. Transcribed presentation to the Advisory Committee for Pharmaceutical Sciences Meeting. Center for Drug Evaluation and Research (CDER). Food and Drug Administration (FDA), Rockville, MD, November 29, 2001; presentation slides available at http://www.fda.gov/ohrms/dockets/ac/01/slides/3804s2_02_Pershing/index.htm; transcript of presentation available at http://www.fda.gov/ohrms/dockets/ac/01/transcripts/3804t2_01_Morning_Session.pdf pp. 31-47.
» http://www.fda.gov/ohrms/dockets/ac/01/slides/3804s2_02_Pershing/index.htm
» http://www.fda.gov/ohrms/dockets/ac/01/transcripts/3804t2_01_Morning_Session.pdf
Raney SG, Franz TJ, Lehman PA, Lionberger R, Chen ML Pharmacokinetics-based approaches for bioequivalence evaluation of topical dermatological drug products. Clin Pharmacokinet. 2015;54:1095-1106. doi: 10.1007 / s40262-015-0292-0.
» https://doi.org/10.1007 / s40262-015-0292-0.
Sekkat N, Guy RH. Biological models to study permeation. In: Testa, B., van der Waterbeemd, H., Folkers, G., Guy, R. (Eds.), Pharmacokinetic Optimisation in Drug Research: Biological, Physicochemical and Computational Strategies. Wiley-VCH, Lausanne, pp. 155-171. 2001.
Shah VP, Yacobi A, Radulescu FS, Miron DS, Lane ME. A science based approach to topical drug classification system (TCS). Int J Pharm . 2015;491(1-2):21-5. doi: 10.1016/j.ijpharm.2015.06.011.
» https://doi.org/10.1016/j.ijpharm.2015.06.011.
Soares KCC, Moraes MV, Gelfuso GM, Gratieri T. Bioequivalence of dermatological topical medicines: the brazilian scenario and the challenges for health surveillance. Ciênc Saúde Coletiva. 2015;20(11):3599-360. DOI: 10.1590/1413-812320152011.01082015.
» https://doi.org/10.1590/1413-812320152011.01082015.
Soares KCC, Souza WC, Teixeira LS, Cunha-Filho MSS, Gelfuso GM, Gratieri T. Comparison of clobetasol propionate generics using simplified in vitro bioequivalence method for topical drug products. Curr Drug Deliv. 2018;15(0): DOI: 10.2174/1567201814666171120125333.
» https://doi.org/10.2174/1567201814666171120125333.
Yacobi A, Shah VP, Bashaw ED, Benfeldt E, Davit B, Ganes D, et al. Current challenges in bioequivalence, quality, and novel assessment technologies for topical products. Pharm Res . 2014;31(4):837-46. doi: 10.1007/s11095-013-1259-1.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
